uniQure (NASDAQ:QURE) Rating Lowered to “Sell” at Wall Street Zen

uniQure (NASDAQ:QURE) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other research analysts have also weighed in on the company. Wells Fargo & Company raised their price objective on uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Thursday. Barclays lowered their price objective on uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research report on Thursday. HC Wainwright increased their target price on uniQure from $50.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Chardan Capital increased their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Leerink Partners raised their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $65.00.

uniQure Stock Performance

NASDAQ:QURE opened at $43.63 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. The firm has a market cap of $3.03 billion, a PE ratio of -10.88 and a beta of 0.93. The firm has a 50 day simple moving average of $37.49 and a 200-day simple moving average of $26.28. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.During the same quarter last year, the business posted ($0.69) EPS. On average, equities analysts expect that uniQure will post -3.74 EPS for the current year.

Insider Buying and Selling

In related news, Director Madhavan Balachandran sold 11,685 shares of uniQure stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director owned 43,254 shares in the company, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jack Kaye sold 21,167 shares of uniQure stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the completion of the transaction, the director owned 25,996 shares in the company, valued at $1,207,254.24. The trade was a 44.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 433,229 shares of company stock worth $17,944,799 over the last 90 days. Company insiders own 4.65% of the company’s stock.

Hedge Funds Weigh In On uniQure

Large investors have recently modified their holdings of the company. Torren Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at about $28,000. IFP Advisors Inc acquired a new stake in uniQure during the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC purchased a new position in uniQure in the fourth quarter valued at approximately $48,000. CIBC Private Wealth Group LLC purchased a new position in uniQure in the third quarter valued at approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 906 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: An analyst raised uniQure’s price target to $75, signaling additional potential upside and supporting investor sentiment. uniQure Price Target Raised to $75.00
• Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target. Its projections still anticipate a shift from losses to profitability over the longer term, including estimated positive EPS of $1.95 in fiscal 2029 and $5.07 in fiscal 2030.
• Neutral Sentiment: The target-price increase provides a constructive valuation signal, although it remains below HC Wainwright’s $80 objective, leaving analysts’ views somewhat mixed.
• Negative Sentiment: HC Wainwright reduced EPS estimates across multiple periods, including fiscal 2026 to a loss of $3.98 per share from $3.38, fiscal 2027 to a loss of $3.87 from $3.46, and fiscal 2028 to a loss of $1.07 from $0.64. The firm also lowered its fiscal 2029 and 2030 profit forecasts, indicating expectations for weaker near- and long-term earnings.
• Negative Sentiment: Wall Street Zen downgraded QURE to a “Sell” rating, adding a bearish counterpoint to the more optimistic HC Wainwright view. uniQure Downgraded to Sell Rating

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.